InnovationRx: Trump Picks RFK, Jr. And Dr. Oz For Key Healthcare Roles [Forbes]
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $62.00. They now have an "overweight" rating on the stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Child Thriving After Becoming World's Youngest to Receive Gene Therapy for AADC Deficiency [Yahoo! Finance]
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain [Yahoo! Finance]